monday august 22 1994 part iv depart health human servic food drug administr 21 cfr part 310 drug product treatment prevent nocturn leg muscl cramp counter human use final rule feder regist vol 59 161 monday august 22 1994 rule regul usdept depart health human servic usdept usbureau food drug administr usbureau 21 cfr part 310 rindock docket 77n0094 rindock rindock rin 0905aa06 rindock drug product treatment prevent nocturn leg muscl cramp counter human use agenc agenc food drug administr hh agenc action action final rule action summari summari food drug administr fda issu final rule establish counter otc drug product treatment prevent nocturn leg muscl cramp gener recogn safe effect misbrand fda issu final rule consid public comment agenc propos regul issu form tent final monograph new data inform drug product treatment prevent nocturn leg muscl cramp come agenc attent final rule part ongo review otc drug product conduct fda summari date effect date februari 22 1995 date inform contact william e gilbertson center drug evalu research hfd810 food drug administr 5600 fisher lane rockvil md 20857 3015945000 supplem supplementari inform feder regist octob 1 1982 47 fr 43562 fda publish 330 10 6 21 cfr 330 10 6 advanc notic propos rulemak reopen rulemak otc intern analges antipyret antirheumat drug product consid otc use quinin treatment nocturn leg muscl cramp togeth recommend advisori review panel otc miscellan intern drug product miscellan intern panel advisori review panel respons evalu data activ ingredi drug class interest person invit submit comment decemb 30 1982 repli comment respons comment file initi comment period could submit januari 31 1983 accord 330 10 10 data inform consid panel put display docket manag branch hfa305 food drug administr rm 123 12420 parklawn dr rockvil md 20857 delet small amount trade secret inform agenc propos regul form tent final monograph otc drug product treatment prevent nocturn leg muscl cramp publish feder regist novemb 8 1985 50 fr 46588 interest person invit file januari 7 1986 written comment object request oral hear commission food drug regard propos interest person invit file comment agenc econom impact determin march 10 1986 new data could submit novemb 10 1986 comment new data could submit januari 8 1987 final agenc action occur public final rule otc drug product treatment prevent nocturn leg muscl cramp preambl agenc propos rule otc drug product treatment prevent nocturn leg muscl cramp 50 fr 46588 agenc state activ ingredi drug product use otc treatment prevent nocturn leg muscl cramp found gener recogn safe effect misbrand categori label propos document event data submit result upgrad ingredi monograph statu final rule final rule ingredi otc drug product treatment prevent nocturn leg muscl cramp determin gener recogn safe effect therefor propos part 343 21 cfr 343 subpart e otc drug product treatment prevent nocturn leg muscl cramp issu final regul final rule declar otc drug product contain activ ingredi treatment prevent nocturn leg muscl cramp new drug section 201 p feder food drug cosmet act act 21 u c 321 p applic abbrevi applic hereinaft call applic approv section 505 act 21 u c 355 21 cfr part 314 requir market absenc approv applic product contain drug use also would misbrand section 502 act 21 u c 352 appropri circumst citizen petit establish monograph may submit 21 cfr 10 30 lieu applic final rule amend 21 cfr part 310 includ drug product contain activ ingredi treatment prevent nocturn leg muscl cramp ad new 310 546 21 cfr 310 546 subpart e inclus otc drug product treatment prevent nocturn leg muscl cramp part 310 consist fda establish polici regul monograph condit see e g 310 510 310 519 310 525 310 526 310 532 310 533 310 534 futur ingredi determin gener recogn safe effect use otc drug product treatment prevent nocturn leg muscl cramp agenc promulg appropri regul time otc drug procedur regul 21 cfr 330 10 provid test necessari resolv safeti effect issu formerli result categori iii classif submiss fda result test data must done otc drug rulemak process establish final monograph accordingli fda use term categori gener recogn safe effect misbrand categori ii gener recogn safe effect misbrand categori iii avail data insuffici classifi safe effect test requir final monograph stage place categori term monograph condit use place categori ii iii term nonmonograph condit use propos rule otc drug product treatment prevent nocturn leg muscl cramp 50 fr 46588 agenc advis would provid period 12 month date public final monograph feder regist relabel reformul drug product treatment prevent nocturn leg muscl cramp complianc monograph although sever manufactur submit data inform respons propos rule data inform suffici support monograph condit monograph establish time therefor drug product treatment prevent nocturn leg muscl cramp subject rule gener recogn safe effect misbrand nonmonograph condit agenc also state safeti problem identifi particular nonmonograph condit shorter deadlin may set remov condit otc drug product state safeti problem identifi otc drug product contain quinin sulfat treatment prevent nocturn leg muscl cramp therefor agenc determin initi introduct initi deliveri introduct interst commerc quinin sulfat treatment prevent nocturn leg muscl cramp must ceas effect februari 22 1995 date otc drug product subject final rule may initi introduc initi deliv introduct interst commerc unless subject approv applic agenc unawar quinin sulfat drug product indic subject approv applic drug product interst commerc effect date final rule complianc regul subject regulatori action respons propos rule otc drug product treatment prevent nocturn leg muscl cramp three drug manufactur nutrit inform servic submit comment one comment includ request oral hear commission food drug administr record close citizen petit submit decemb 1 1988 respons petit nine addit comment submit commission found petit subsequ comment rais safeti effect issu warrant consider final rule issu accordingli 330 10 7 v commission determin good caus shown warrant consider petit addit comment final rule issu copi comment receiv petit public display docket manag branch address addit inform come agenc attent sinc public propos rule also public display docket manag branch agenc conclus comment gener comment 1 one comment disagre agenc determin adequ clinic data exist support categori statu quinin safeti effect otc use treatment prevent nocturn leg muscl cramp 50 fr 46588 46590 comment express belief suffici evid alreadi exist use quinin support posit comment refer inform submit decemb 27 1982 respons advanc notic propos rulemak class drug product agenc discuss inform tent final monograph 50 fr 46588 46589 conclud provid suffici evid establish quinin gener recogn safe effect otc use treatment prevent nocturn leg muscl cramp agenc identifi issu address studi quinin could reclassifi categori iii categori 50 fr 46590 46591 comment provid new inform address issu new data inform submit interest person discuss section b comment 4 9 document b comment safeti nocturn leg muscl cramp ingredi 2 two comment contend fda accept safe otc use quinin sulfat nocturn leg cramp publish dissent miscellan intern panel conclus recommend quinin appear reason safe prolong period time gener recommend dose 200 325 mg daili 47 fr 43562 43564 contrari comment content record make clear neither agenc advisori panel accept safeti otc use quinin nocturn leg muscl cramp juli 8 1977 report advisori review panel otc intern analges antirheumat drug product 42 fr 35346 35434 summar safeti quinin state although quinin demonstr analges antipyret muscl relax action numer toxic effect give unfavor benefit risk ratio purpos panel conclud control studi show dose 325 mg daili safe use relief nocturn leg cramp drug avail otc use treatment nocturn leg cramp miscellan intern panel report state quinin appear reason safe 47 fr 43564 panel conclud quinin safe dose use treatment nocturn leg muscl cramp panel recommend quinin place categori iii use treatment nocturn leg muscl cramp cite need inform safeti efficaci conclud statement 47 fr 43564 tent final monograph otc drug product treatment prevent nocturn leg muscl cramp agenc concur 1 miscellan intern panel classif quinin sulfat categori iii 2 intern analges panel conclus drug gener recogn safe effect categori ii use safeti efficaci demonstr control clinic trial 50 fr 46588 46592 clear therefor neither agenc advisori panel determin quinin may safe use indic 3 three comment state quinin safe use million consum varieti condit includ leg cramp 50 year long histori usag demonstr safeti quinin gener refer histori use quinin cannot accept evid safeti histor clear locat organ collect analysi advers drug experi report otc drug product advers event associ otc drug product still vastli underreport number reason first otc drug requir manufactur distributor report advers event fda even seriou life threaten second physician princip report unit state spontan report system may becom awar reaction otc drug patient often mention otc drug give medic histori often clear physician manufactur advers event report 4 two comment support keep quinin avail otc discuss advers event report file quinin fda spontan report system lavi ref 1 state 52 report suggest hypersensit reaction includ 8 death among report file 1969 1988 lavi concentr report thrombocytopenia decreas number blood platelet state bleed secondari thrombocytopenia may relat four eight death report 20 year period comment state one case provid suffici inform fulfil diagnost criteria drug induc immunolog thrombocytopenia consist clinic histori exclus caus posit vitro test theoret demonstr recurr thrombocytopenia rechalleng lavi point advers event report reflect signific preval sever quinin associ purpura occur reaction readili identifi patient physician hospit use industri quinin sale figur data fda spontan report system lavi conclud number report quinin relat hypersensit reaction quit low even greatli underreport aster ref 2 review advers drug reaction report fda 1969 decemb 1989 estim approxim 1 000 reaction 313 individu report quinin aster estim limit hypersensit reaction includ report reaction includ multipl reaction per individu aster report specif search criteria use obtain advers drug reaction report state fda materi provid cumul list advers drug reaction adr report connect quinin sinc 1969 elimin reaction consid highli unlik bear caus effect relationship quinin aster identifi 254 reaction consid signific 83 hematolog reaction 46 addit reaction possibl associ hypersensit 63 possibl case thrombocytopenia 36 includ inform verifi low platelet level aster identifi 50 fatal 15 hematolog complic 3 hypersensit 32 caus overal aster classifi 51 percent advers reaction idiosyncrat eight percent result overdos remain 41 percent indetermin etiolog consist liver kidney dysfunct neurolog disord variou hemorrhag manifest report inadequ inform provid full evalu aster note possibl six cerebrovascular accid report may associ thrombocytopenia induc quinin aster conclud 1 inform avail would enabl identif peopl risk sensit reaction quinin 2 rariti sensit reaction rapid occur make earli detect reaction imposs 3 dramat symptomatolog reaction occur lead peopl seek prompt medic attent aster conclud therefor seriou advers reaction would neither prevent reduc incid restrict quinin avail prescript statu agenc review comment report advers reaction quinin product list agenc spontan report system quinin quinin sulfat three brand name product use treatment prevent nocturn leg muscl cramp 1969 june 1992 fda receiv 157 advers reaction report quinin list suspect drug 84 seriou reaction 23 death 5 case person disabl 56 hospit involv death disabl 157 advers reaction report 52 approxim 33 percent contain dosag product name inform report daili dosag excess typic recommend treatment prevent nocturn leg muscl cramp remain 105 report list name quinin product label use treatment prevent nocturn leg muscl cramp daili dosag recommend product includ 60 seriou reaction involv 16 death 4 case disabl 40 hospit involv death disabl importantli 56 105 report approxim 53 percent receiv sinc 1988 alarm trend increas number report per year sinc 1986 market otc drug product contain quinin treatment prevent nocturn leg muscl cramp expand period approxim 70 percent 42 60 report seriou reaction 44 percent 7 16 report death 78 percent 31 40 report hospit file sinc 1969 report 4 1 2 year period januari 1988 juli 1992 20 case 19 percent report file report 1991 alon 3 disabl 11 requir hospit 1 result death nocturn leg muscl cramp common condit elderli ref 3 presum increas averag age american popul market otc drug product contain quinin treatment prevent nocturn leg muscl cramp also increas period number advers reaction report peopl 60 year age older involv quinin product quinin dosag use treatment prevent nocturn leg muscl cramp increas factor five 2 10 period januari 1988 decemb 1991 agenc conduct detail review 110 report file 1969 1990 69 approxim 63 percent report involv hypersensit reaction rang rash fever angioneurot edema thrombocytopenia gener anaphylaxi 69 report 57 approxim 83 percent involv quinin product quinin dosag use treatment prevent nocturn leg muscl cramp attempt made identifi report relationship quinin report event strong reason unrel factor factor consid includ tempor relationship quinin administr event absenc concomit medic abat advers event quinin discontinu absenc confound medic condit posit test quinin mediat antibodi histori similar reaction associ previou quinin exposur use factor 110 report 26 identifi reason conclud quinin caus agent includ 6 moder sever sever skin reaction 2 erythema multiform like reaction 13 hematolog event 2 result death 2 case hepat elev liver enzym 2 renal reaction one lead renal failur requir dialysi lead death 2 case hypersensit syndrom symptom includ chill nausea vomit diarrhea 1 report anaphylaxi complic seizur hypoxia follow singl dose quinin none case report overdos drug 21 26 report approxim 81 percent involv quinin product quinin dosag use treatment prevent nocturn leg muscl cramp even use strict criteria identifi case causal relationship quinin advers event like fda find quinin associ seriou advers event compel reason restrict evalu safeti quinin report case thrombocytopenia lavi advers effect also seriou must consid weigh benefit risk product contain quinin agenc agre aster current way advanc identifi peopl risk hypersensit reaction therefor effect way warn use individu see section b comment 10 agre howev physician monitor might minim seriou reaction thrombocytopenia exampl lead bruis evid cutan bleed physician could warn patient report sign stop drug perhap prevent signific hemorrhag event refer 1 lavi n w overview efficaci safeti quinin sulfat treatment prevent nocturn leg cramp unpublish report sup00033 docket 77n0094 docket manag branch 2 aster r h q vel could seriou advers reaction prevent drug avail prescript unpublish report comment c176 docket 77n0094 docket manag branch 3 jone k c castleden doubl blind comparison quinin sulphat placebo muscl cramp age age 12 2 155158 1983 5 sever comment contend true incid quinin induc thrombocytopenia mani time smaller suggest estim base event report exposur quinin contain drug product alon comment contend estim fail account much larger exposur quinin beverag lavi estim exposur quinin beverag 10 time greater exposur quinin drug product ref 1 agenc search medic literatur identifi 10 case hypersensit reaction attribut quinin beverag ref 2 9 one reaction occur follow ingest drug product contain quinin person presum previous sensit exposur beverag ref 5 none event fatal agenc find avail inform support safe use quinin beverag tonic water bitter lemon given level consumpt quinin beverag scarciti report hypersensit reaction even assum reaction food product vastli underreport despit safeti data beverag use agenc consid pool total consumpt advers reaction data quinin food drug product legitim basi judg safeti drug product contain quinin first differ quinin exposur level quinin present much greater amount drug product second great dispar incid report hypersensit reaction beverag drug product agenc consid appropri basi estim incid hypersensit quinin contain drug product leg cramp suffer evalu report reaction peopl take product dose frequenc durat recommend product label adjust report incid reaction drug product pool data beverag erron exagger risk reaction quinin beverag vastli underestim risk reaction quinin contain drug product contradict raw data product number sever report hypersensit reaction drug product contain quinin rais safeti concern product see section b comment 4 agenc consid virtual absenc report reaction beverag contain small amount quinin e 83 part per million support safeti use thu use quinin salt food accord condit describ 21 cfr 172 575 affect final rule drug product treatment prevent nocturn leg muscl cramp refer 1 lavi n w overview efficaci safeti quinin sulfat treatment prevent nocturn leg cramp unpublish report sup00033 docket 77n0094 docket manag branch 2 belkin g cocktail purpura unusu case quinin sensit annal intern medicin 66 3 583586 1967 3 korbitz b c e eisner cocktail purpura quinin depend thrombocytopenia rocki mountain medic journal 70 10 3841 1973 4 siroti r r purpura rock twist journal american medic associ 235 23 25212522 1976 5 elliott h l b trash intraven coagul induc quinin scottish medic journal 24 3 244245 1979 6 murray j et al bitter lemon purpura british medic journal 2 6204 15511552 1979 7 calnan c g caron quinin sensit british medic journal 2 17501752 1961 8 cundal r idiosyncrasi quinin bitter lemon british medic journal 1 1638 1964 9 callaway j l w e tate toxic epiderm necrolysi caus gin tonic archiv dermatolog 109 909 1974 6 four comment submit five report ref 1 5 control clinic studi quinin alon combin vitamin e agenc review studi evid pertain safeti quinin use treat prevent nocturn leg muscl cramp first studi ref 1 10 week crossov studi 69 subject random either 260 milligram mg quinin sulfat placebo subject 26 77 year age mean age 51 five advers reaction quinin 7 percent incid report one subject unabl toler quinin tinnitu ring ear ear occur take studi drug two addit subject experienc tinnitu take quinin continu medic complet studi although protocol call discontinu studi drug ring ear occur one addit subject experienc disorient anoth report dizzi take quinin advers event placebo report second studi ref 2 10 week doubl blind random crossov studi 62 subject receiv daili dose either 325 mg quinin sulfat placebo subject 21 76 year age mean age 47 three subject quinin three subject placebo report advers event quinin reaction includ tinnitu quickli resolv drug discontinu blur vision headach occur 3 day drug administr one subject drop studi dizzi drowsi anoth subject discontinu quinin last two day treatment period tinnitu placebo group one subject report chest pain heartburn anoth subject experienc fever nausea one subject report constip drop studi addit eight subject drop studi reason describ report relat drug product detail provid third studi ref 3 5 week random crossov studi involv 205 subject randomli assign quinin sulfat 260 mg day vitamin e 1 600 intern unit u day combin quinin vitamin e dose placebo subject 18 80 year age mean age 44 twenti seven advers reaction report 9 4 4 percent subject receiv combin quinin vitamin e 8 3 9 percent subject quinin alon 6 2 9 percent subject vitamin e alon 4 2 percent subject receiv placebo almost twofold differ overal advers experi subject take either test drug contain quinin advers event subject receiv quinin alon includ stomach cramp headach nausea diarrhea swollen hand slight muscl twitch advers event subject receiv quinin vitamin e combin includ upset stomach headach diarrhea tired constip pain leg advers effect subject receiv vitamin e includ abdomin cramp vomit loos bowel headach intensifi menstrual cramp advers event placebo group includ nausea stomach cramp tingli finger gastrointestin disturb report twice mani subject take quinin alon combin assign vitamin e alon placebo advers experi studi irrespect treatment group describ investig relat probabl relat studi medic report event howev consist classic associ quinin toxic includ gastrointestin symptom nausea vomit abdomin pain diarrhea vasodil sweat headach tinnitu vertigo visual disturb ref 6 fourth studi ref 4 5 week crossov studi involv 24 subject 51 64 year age mean age 57 subject receiv placebo week 1 3 5 half subject assign quinin sulfat 260 mg per day half combin quinin sulfat vitamin e week 2 week 4 subject combin week 2 assign quinin alon vice versa nausea report 3 subject 12 5 percent receiv quinin sulfat week 2 detail report reaction provid advers event report fifth largest studi multicent block random parallel design involv 559 subject 18 84 year age ref 5 1 week singl blind placebo phase follow 2 week doubl blind random treatment phase subject least one leg cramp per night minimum 3 night singl blind placebo week met select criteria random one four doubl blind treatment group quinin sulfat 259 2 mg subject age rang 19 79 year mean age 46 vitamin e 1 600 u subject age rang 18 76 year mean age 42 combin quinin vitamin e dose subject age rang 18 83 year mean age 46 placebo subject age rang 21 84 year mean age 45 besid meet criteria frequenc nocturn leg cramp subject admit studi gener good health predominantli femal mean age less 50 year studi report state unexpect idiosyncrat advers event seen among patient take effect cours therapi higher usual incid recogn advers drug reaction associ ingest quinin one subject random combin product report experienc reaction consist fever headach nausea vomit diffus muscl pain 5 day episod suffici sever warrant medic intervent test drug quinin vitamin e stop subject treat analges antipyret therapi prescript antiemet symptom subsid 3 day studi medic resum subject experienc nausea vomit abdomin pain sever headach diffus myalgia sever pain leg fever subject requir hospit therefor studi drug stop subject discharg 5 day later physician advis consid sensit quinin given tempor relationship onset symptom administr studi drug well posit rechalleng case appear well document hypersensit reaction addit anoth subject quinin experienc itch nausea vomit discontinu drug two subject experienc moder sever wheez 8th 12th day quinin treatment neither subject discontinu medic overal incid advers event report fifth studi ref 5 high approxim equal group quinin sulfat 43 3 percent vitamin e 37 2 percent combin quinin sulfat vitamin e 39 3 percent placebo 41 3 percent headach account greatest number report event group quinin sulfat 19 1 percent vitamin e 16 8 percent combin quinin sulfat vitamin e 19 1 percent placebo 21 percent appear treatment relat differ side effect profil treatment emerg event incid 1 percent consid headach event consid investig relat studi drug exclud analysi show advers event rate 12 8 percent quinin sulfat nausea vomit diarrhea dizzi tinnitu pruritu urticaria 3 6 percent vitamin e nausea myalgia 12 percent combin product nausea vomit diarrhea tinnitu fever none event report subject placebo investig consid potenti relat studi drug incid 1 percent similarli event report sever moder sever exclud headach event incid less 1 percent frequent subject take quinin sulfat 6 4 percent combin product 7 1 percent vitamin e alon 3 6 percent placebo 2 2 percent potenti symptom quinin toxic low dose gener recommend otc treatment prevent nocturn leg muscl cramp confirm sever studi ref 7 8 9 recent studi relationship plasma quinin level hear impair ref 7 found quinin even low dose produc auditori chang studi singl oral dose quinin 5 milligram kilogram mg kg 10 mg kg 15 mg kg administ six healthi femal 24 39 year age studi specifi subject weight subject weight 50 60 kg assum dose would correspond singl quinin dose 250 300 mg 500 600 mg 750 900 mg respect even lowest dose equival dose use otc drug product treatment prevent nocturn leg muscl cramp drug effect hear impair detect half subject plasma concentr exceed 15 micromol liter mmol l subject hear loss tinnitu observ subject symptom detect level 5 mmol l shift hear threshold equal frequenc rang studi effect time consist level dose given investig conclud consist effect concentr relationship hear impair caus quinin defin audiometri zajtchuk ref 8 compar effect vestibular auditori function 0 52 5 mg 105 mg quinin administ form commerci tonic water contain 52 5 mg quinin per 822 millilit ml bottl 17 activ duti militari personnel studi initi follow find low level quinin post mortem tissu militari pilot fatal tonic water administ 3 hour period daili 14 day control subject subject given low dose normal function throughout test three four subject given 105 mg day develop transient vestibular abnorm manifest rapid involuntari rhythmic movement eyebal associ certain posit head bodi posit test worden shephard frape ref 9 conduct two similar studi one studi 6 men 14 women 18 39 year age given 100 mg quinin hydrochlorid daili form tonic water 14 day second studi 4 men 6 women 18 53 year age divid 2 group one group receiv 120 mg fortifi tonic water drank carbon drink without quinin audiometr chang found subject either studi howev 12 subject 60 percent first studi complain visual disturb 14 70 percent report dizzi 14 70 percent experienc headach potenti advers effect quinin may greater elderli survey one hospit ref 10 201 inpati 70 year age older found 23 11 percent take quinin cramp sixti percent take 300 mg nightli 40 percent take twice amount 600 mg nightli approxim one third subject take drug continu chronic 2 year author note mean elimin half life quinin elderli patient report 19 hour compar 8 5 hour younger adult author also state chronic therapi like result accumul quinin put elderli patient greater risk advers effect possibl advers effect includ symptom cinchon tinnitu headach nausea rash visual disturb temporari blind allerg reaction thrombocytopenia haemolyt anaemia wanwimolruk et al ref 11 found elimin half life quinin 18 4 5 7 hour 8 healthi elderli subject 65 78 year old compar 10 5 1 6 hour 12 subject 20 35 year old furthermor significantli greater amount quinin excret unchang elderli subject suggest quinin metabol reduc elderli peopl overal 26 percent reduct clearanc quinin older group author conclud accumul quinin may occur elderli peopl thu place greater risk advers event studi indic seriou safeti concern exist regard otc avail quinin sulfat treatment prevent nocturn leg muscl cramp subject studi submit gener good health mean age 44 57 year variou group howev advers reaction report studi suggest quinin dose 260 325 mg day healthi middl age adult produc symptom quinin toxic includ auditori visual gastrointestin effect studi ref 7 8 9 suggest vestibular auditori visual vascular effect quinin occur healthi young adult dose rang commonli employ treatment prevent nocturn leg muscl cramp alter pharmacokinet age also result longer half life quinin older peopl longer half life increas frequenc sever advers effect elderli ref 11 group leg cramp common condit ref 12 13 therefor agenc conclud quinin safe otc use treatment prevent nocturn leg muscl cramp refer 1 bottner clinic trial efficaci quinin sulfat treatment nocturn leg muscl cramp protocol 8446 draft unpublish paper comment c123 docket 77n0094 docket manag branch 2 hay r j j goodman clinic trial efficaci quinin sulfat treatment nocturn leg muscl cramp protocol 8648 draft unpublish paper comment c126 docket 77n0094 docket manag branch 3 leo winter associ inc final medic report data summari analysi final statist report doubl blind random crossov studi q velr versu quinin sulfat versu vitamin e versu placebo treatment nocturn leg muscl cramp 12855082 draft unpublish paper comment sup00031 docket 77n0094 docket manag branch 4 biodesign gmbh clinic evalu q velr patient nocturn leg muscl cramp draft unpublish paper comment sup00031 docket 77n0094 docket manag branch 5 draft unpublish studi entitl short term random doubl blind parallel studi q vel vs quinin sulfat vs vitamin e vs placebo prevent treatment nocturn leg cramp comment sup00033 docket 77n0094 docket manag branch 6 bateman n e h dyson quinin toxic advers drug reaction acut poison review 4 215233 1986 7 alvan g et al hear impair relat plasma quinin concentr healthi volunt british journal clinic pharmacolog 31 409412 1991 8 zajtchuk j et al electronystagmograph find long term low dose quinin ingest archiv otolaryngolog 110 788791 1984 9 worden n n w shephard l frape report daili consumpt 14 day normal subject tonic water contain quinin hydrochlorid unpublish report copi otc vol 03afm docket 77n0094 docket manag branch 10 blackbourn j bajrov quinine_forev ever hospit pharmaci 23 732 735 1988 11 wanwimolruk et al pharmaco kinet quinin young elderli subject transact royal societi tropic medicin hygien 85 6 714717 1991 12 grigg r c pain spasm cramp muscl harrison principl intern medicin 12th ed edit j wilson et al mcgraw hill inc new york pp 173176 1991 13 jone k c castleden doubl blind comparison quinin sulphat placebo muscl cramp age age 12 2 155158 1983 7 one comment ref 1 request ban otc market quinin sulfat product use treatment nocturn recumb leg cramp comment base request part advers reaction report fda includ eight death describ close link quinin product comment contend seriou fatal advers reaction quinin sulfat purchas otc use continu report comment mention reaction occur sever way 1 person hypersensit quinin 2 innat toxic quinin 3 result interact drug includ digoxin anticoagul antiarrhythm comment conclud risk associ quinin use leg cramp unaccept light lack efficaci use agenc agre quinin potenti elicit seriou hypersensit reaction dose employ otc drug product use treatment prevent nocturn leg muscl cramp agenc spontan advers reaction report system includ reason unconfound report thrombocytopenia hemolyt anemia leukopenia granulocytopenia anaphylaxi hypersensit syndrom sever skin reaction includ urticaria angioedema erythema multiform liver abnorm renal failur death see section b comment 4 report literatur identifi quinin sulfat dose typic recommend treatment prevent nocturn leg muscl cramp caus agent case photosensit dermat ref 2 3 4 psychosi ref 5 dissemin intravascular coagul ref 6 hemolyt urem syndrom ref 7 agenc agre quinin may interact sever drug ref 8 9 10 includ mention comment inform could includ label otc quinin drug product howev agenc need make decis drug interact precaut ingredi treat prevent nocturn leg muscl cramp current gener recogn safe effect inclus otc drug monograph cinchon cluster symptom vari sever includ tinnitu dizzi disorient nausea visual chang auditori deficit higher dose cardiac arrhythmia cinchon dose relat clinic studi discuss section b comment 6 demonstr advers event typic quinin toxic case suffici sever lead discontinu drug occur peopl dose gener recommend treatment prevent nocturn leg muscl cramp studi indic peopl self medic quinin treat prevent nocturn leg muscl cramp dose recommend product label experi quinin relat advers event addit peopl take quinin remain risk develop hypersensit drug experienc seriou life threaten fatal reaction consequ even quinin effect treatment prevent nocturn leg muscl cramp risk would requir prescrib physician particip decis use drug assur diagnosi consid altern treatment option evalu concurr medic problem medic monitor patient safeti throughout treatment refer 1 comment cp0006 docket 77n0094 docket manag branch 2 diffey b l et al action spectrum quinin photosensit british journal dermatolog 118 679685 1988 3 ferguson j et al quinin induc photosensit clinic experiment studi british journal dermatolog 117 63140 1987 4 ljunggren b p sjoval system quinin photosensit archiv dermatolog 122 909911 1986 5 verghes c quinin psychosi british journal psychiatri 153 575576 1988 6 spear r l et al quinin induc dissemin intravascular coagul lancet 336 15351537 1990 7 gottschal j l et al quinin induc immun thrombocytopenia associ hemolyt urem syndrom new clinic entiti blood 77 2 306310 1991 8 lavi n w overview efficaci safeti quinin sulfat treatment prevent nocturn leg cramp unpublish report sup00033 docket 77n0094 docket manag branch 9 uspdi drug inform health care profession u pharmacopei convent inc rockvil md vol 14th ed pp 23792382 1994 10 drug evalu subscript american medic associ chicago 1 4 1011 1993 8 sever comment downplay potenti hypersensit reaction quinin particularli quinin induc immunolog thrombocytopenia argu continu otc market quinin treatment prevent nocturn leg muscl cramp stop potenti consequ use one comment ref 1 submit expert review drug induc immunolog thrombocytopenia diitp state diitp report 100 drug gold salt heparin cinchona alkaloid drug commonli associ condit accord expert review suppli comment known inform dose quinin requir induc diitp sensit diitp occur frequent peopl 50 year old possibl greater exposur drug typic character warm sensat follow chill bleed episod manifest petechia pinpoint red spot caus intraderm submucos hemorrhag purpura purplish brownish red discolor visibl skin caus hemorrhag tissu hemorrhag lesion oral mucosa occasion hemorrhag gastrointestin urinari tract may occur 6 12 hour drug exposur individu develop sever thrombocytopenia intracerebr hemorrhag lethal intrapulmonari hemorrhag report primari treatment discontinu offend drug bleed usual subsid 3 4 day intervent includ glucocorticoid therapi platelet transfus shown benefici anoth comment argu mani drug addit food propens induc varieti advers reaction ref 2 comment state preval hypersensit tartrazin fdc yellow 5 wide use dye estim 1 10 000 gener popul comment point tartrazin use otc drug product label statement requir inform consum product contain tartrazin may caus allerg type reaction comment state clear preced otc drug use product potenti rare hypersensit comment also describ aspirin sensit widespread emphas brief warn statement label regard use peopl asthma aspirin sensit deem adequ ensur safe otc use agenc find inform first comment indic quinin one drug frequent associ diitp drug e g gold salt heparin caus diitp quinin drug highli associ diitp avail otc march 1985 depart health human servic establish ad hoc advisori committe hypersensit food constitu committe evalu data relev allerg type reaction human associ food constitu committe conclud tartrazin may caus mild case urticaria hive small subset popul usual requir medic intervent committe found evid color addit constitut hazard gener public use food current level prior committe find agenc decid label provid adequ safeguard sensit tartrazin see feder regist februari 4 1977 42 fr 6835 june 26 1979 44 fr 37212 agenc requir label otc prescript drug product contain tartrazin intend oral nasal rectal vagin use specif declar presenc tartrazin list color addit use name fdc yellow 5 tartrazin see 21 cfr 74 1705 c 2 addit label statement prescript drug product use must also includ label warn statement product contain fdc yellow 5 tartrazin may caus allerg type reaction includ bronchial asthma certain suscept person although overal incid fdc yellow 5 tartrazin sensit gener popul low frequent seen patient also aspirin hypersensit number differ hypersensit reaction tartrazin aspirin hypersensit reaction quinin review allerg reaction drug addit ref 3 simon state reaction tartrazin occur inde quit rare asthmat popul even aspirin sensit subpopul simon report posit respons found 125 doubl blind placebo control tartrazin challeng least 25 mg aspirin sensit asthmat popul simon also review advers reaction food addit ref 4 state although tartrazin food addit frequent associ hypersensit reaction tartrazin confirm best occasion associ flare urticaria asthma report rel mild tartrazin reaction howev contrast seriou report quinin involv life threaten fatal hypersensit reaction virchow et al ref 5 evalu sensit tartrazin 156 european confirm aspirin induc asthma oral challeng perform increas dose posit challeng repeat doubl blind condit four subject posit reaction none seriou incid tartrazin cross sensit aspirin european popul 2 6 percent similar studi moral et al ref 6 conduct 141 challeng test 47 subject asthma associ intoler analges use tartrazin dose 5 25 50 100 200 mg placebo five test posit four subject repeat test neg three four subject author state clinic instabl subject may caus respiratori symptom attribut tartrazin practic recommend color free diet reserv case posit challeng test obtain least two occas experi suggest 1 incid tartrazin sensit may overestim 2 natur reaction tartrazin suffici benign permit multipl rechalleng confirm intoler rechalleng quinin sensit individu contrast contraind reaction seriou life threaten fatal even control condit safford ref 7 unabl detect antibodi format tartrazin metabolit anim studi suggest immunolog respons involv tartrazin sensit hypersensit quinin contrast mediat immunolog mechan aspirin sensit rel common compar quinin sensit manag usual predict review aspirin sensit settipan ref 8 describ number factor predict subject intoler like occur sensit seen 23 28 percent peopl chronic urticaria 14 23 percent peopl nasal polyp 19 percent peopl asthma peopl like doctor care told avoid aspirin product genton et al ref 9 studi use oral provoc test aspirin food addit 34 subject asthma chronic urticaria conclud investig safe use manag subject identifi intoler variou compound tartrazin hypersensit aspirin appear mediat immunolog respons ref 8 contrast aspirin predict factor quinin hypersensit note vivo rechalleng contraind sensit aspirin ref 8 tartrazin ref 10 problem manag sensit gener result urticari bronchospast symptom respons medic treatment anaphylaxi report aspirin extrem rare given extens use product contain aspirin retrospect studi anaphylaxi occur outsid hospit hospit catchment area denmark 13 year period rate anaphylaxi caus aspirin 0 48 case per 100 000 inhabit ref 11 sensit quinin contrast aspirin tartrazin affect number bodi system may seriou manifest urticaria angioedema hepat injuri renal failur seriou dermatolog condit seriou hematolog event death ref 12 also see section b comment 6 three sourc estim incid quinin induc immunolog thrombocytopenia rang 1 1 000 1 3 000 see section b comment 9 fda spontan report system contain 110 case report involv quinin period 1969 1990 sixti nine approxim 63 percent report repres possibl hypersensit reaction includ 22 report thrombocytopenia 57 case approxim 83 percent involv quinin product quinin dosag typic use treatment prevent nocturn leg muscl cramp eight death occur among report hypersensit reaction medic record autopsi find suffici complet two case involv otc quinin product indic treatment leg muscl cramp implic quinin induc thrombocytopenia precipit fatal hemorrhag case underreport reaction agenc spontan report system believ substanti otc drug product may due physician princip report spontan report system becom awar reaction otc drug manufactur distributor gener requir transmit report seriou advers reaction involv otc drug fda agenc conclud sever quinin hypersensit reaction even first occurr inabl identifi predispos factor occurr creat risk clearli differ present tartrazin aspirin agenc consid like warn statement quinin product label would signific valu imposs prospect identifi group risk see section b comment 10 refer 1 aster r h thrombocytopenia induc quinin drug unpublish report comment c143 docket 77n0094 docket manag branch 2 lavi n w overview efficaci safeti quinin sulfat treatment prevent nocturn leg cramp unpublish report sup00033 docket 77n0094 docket manag branch 3 simon r advers reaction drug addit journal allergi clinic immunolog 74 4 pt 2 623630 1984 4 simon r advers reaction food addit new england region allergi proceed 7 6 533542 1986 5 virchow c et al intoler tartrazin aspirin induc asthma result multicent studi respir 53 1 2023 1988 6 moral c et al challeng test tartrazin patient asthma associ intoler analges asa triad compar studi placebo clinic allergi 15 1 5559 1985 7 safford r j b f goodwin immunolog studi tartrazin metabolit anim studi intern archiv allergi appli immunolog 77 3 331336 1985 8 settipan g aspirin allerg diseas review american journal medicin 74 6a 102109 1983 9 genton c p c frei pecoud valu oral provoc test aspirin food addit routin investig asthma chronic urticaria journal allergi clinic immunolog 76 1 4045 1985 10 dipalma j r tartrazin sensit american famili physician 42 5 13471350 1990 11 sorensen h b nielsen j ostergaard nielsen anaphylact shock occur outsid hospit allergi 44 4 288290 1989 12 bateman n e h dyson quinin toxic advers drug reaction acut poison review 4 215233 1986 9 two comment provid estim incid quinin induc immunolog thrombocytopenia qiitp lavi ref 1 present sever estim base differ assumpt inform one estim lavi note four six hypersensit reaction report fda 1987 case thrombocytopenia lavi convert total sale quinin drug product 1987 dosag unit total number day therapi sold divid number tablet capsul sold dose per day describ product label lavi assum quinin taken leg cramp approxim one quarter year subject divid total day therapi purchas total day use per person lavi estim size popul expos drug product contain quinin 1987 1 66 x 106 calcul incid qiitp 1 case per 415 000 peopl base upon 4 case report fda year lavi tri correct underreport use anoth approach lavi report quinin estim caus agent approxim 10 percent drug induc immunolog thrombocytopenia report note secondari thrombocytopenia princip diagnosi approxim 4 000 discharg 1987 nation hospit discharg survey assum 10 percent thrombocytopenia case drug induc 10 percent drug induc immunolog thrombocytopenia case relat quinin 40 case could attribut quinin assum popul expos drug product contain quinin 1987 1 66 x 106 calcul lavi calcul incid qiitp 1 41 500 lavi cite third estim incid qiitp base inform danielsen report drug induc blood disord among admiss group health cooper puget sound ref 2 retrospect studi 6 case thrombocytopenia relat quinin quinidin among 5 089 subject report appar incid 1 case per 848 subject take 1 2 drug anoth comment ref 3 estim incid qiitp ingest drug product 1 3 300 per year comment base calcul number case document quinin induc thrombocytopenia blood center southeastern wisconsin 10 year period make estim assum least half case occur popul would refer laboratori confirm diagnosi agenc note estim incid thrombocytopen reaction drug product contain quinin rang 1 1 000 quinin quinidin consid togeth less 1 400 000 wide rang suggest precis estim hard obtain difficult conclud howev first estim propos lavi correct number event use lavi number report fda 1987 one know extent underreport believ substanti exampl even 1 percent rate assum would translat use lavi figur 1 4 000 peopl exposur estim could also consider error lavi assum drug use one quarter year person fact use one half year number expos peopl would half propos rate drug induc immunolog thrombocytopenia would doubl calcul incid calcul base nation hospit discharg survey ref 1 employ estim popul discuss assum 1 percent diagnos secondari thrombocytopenia attribut quinin way know accuraci estim higher even factor 5 estim rate would 1 10 000 substanti rate probabl credibl lavi estim puget sound base estim ref 2 base hospit diagnos well document exposur estim incid qiitp base number document case occur popul serv blood center southeastern wisconsin 10 year period ref 3 also base rel assumpt appear reliabl assumpt calcul twice mani event occur report laboratori estim two sourc 1 848 puget sound 1 3 300 southeastern wisconsin similar estim 1 1 000 cite mitchel ref 4 three sourc provid reason small rang incid qiitp expect 1 1 000 1 3 000 therefor agenc believ precis estim incid qiitp difficult obtain credibl estim three sourc ref 2 3 4 support assert qiitp rare event refer 1 lavi n w overview efficaci safeti quinin sulfat treat ment prevent nocturn leg cramp unpublish report sup00033 docket 77n0094 docket manag branch 2 danielson et al drug induc blood disord journal american medic associ 252 23 32573260 1984 3 aster r h thrombocytopenia induc quinin drug unpub lish report comment c143 docket 77n0094 docket manag branch 4 mitchel r j morrow quinin purpura journal tennesse medic associ 81 9 578 1988 10 three comment contend warn product label could adequ inform protect consum well known side effect quinin includ idiosyncrat reaction one comment state warn recommend miscellan intern panel 47 fr 43562 43564 includ concern idiosyncrat reaction incorpor label current market product anoth comment state care warn languag product label help protect consum inform possibl untoward idiosyncrat reaction label state discontinu use consult doctor immedi swell bruis skin rash skin discolor bleed occur symptom may indic seriou condit discontinu use ring ear deaf diarrhea nausea visual disturb occur take allerg sensit quinin 12 year age third comment cite report lavi ref 1 state seriou advers effect occur frequenc probabl less 1 40 000 peopl see section comment 9 clinic cours rare complic label clearli concis warn regard common yet low frequenc side effect gener treat simpli discontinu use tent final monograph 50 fr 46588 46592 agenc propos follow warn 343 150 c otc drug product contain quinin discontinu use ring ear deaf skin rash visual disturb occur take pregnant sensit quinin 12 year age agenc propos label event data submit result inclus quinin monograph final rule propos label requir time agenc review warn inform current appear otc quinin product market treatment prevent leg muscl cramp languag vari slightli product inform provid similar gener label warn patient discontinu take drug number list event occur howev label differ event list recommend physician contact sever factor argu suffici label warn protect consum seriou advers event relat quinin frequenc reaction probabl greater assum comment see section b comment 9 mani advers advent unpredict exampl thrombocytopenia may occur 1 week exposur month year quinin administr may characterist would predict advers event person use product agenc believ physician could help peopl use drug appreci natur frequenc risk help consider whether risk accept physician could also advis sign thrombocytopenia petechia pinpoint nonrais round purplish red spot purpura small hemorrhag perhap allow identif condit signific hemorrhag occur number advers reaction report note occurr similar prior event relat previou ingest quinin neither user physician recogn relationship ill quinin ingest use quinin physician prescript appropri emphasi warn sign may make time recognit easier although drug induc immunolog thrombocytopenia may best studi idiosyncrat reaction caus quinin ref 2 quinin also report associ number hypersensit reaction pharmacolog effect lavi ref 1 note includ possibl decreas digoxin clearanc increas half life quinin given concurr cimetidin pseudo allerg reaction aspirin sensit patient drug fever nonspecif granulomat hepat asthma hemolyt anemia inhibit tolbutamid metabol hypoprothrombinemia hemolyt anemia glucos 6 phosphat dehydrogenas g6pd defici patient etc cooper bunn ref 3 report g 6 pd defici individu e variant suscept hemolyt anemia quinin rel common among eastern mediterranean chines peopl quinin may also interact sever drug see section b comment 7 furthermor possibl pharmacolog effect may particular signific elderli may take concomit medic either provok muscl cramp advers interact quinin alter pharmacokinet age also result longer half life quinin older peopl suggest frequenc sever advers effect may greater elderli ref 4 also see section b comment 6 forego possibl addit advers reaction includ relat ethnic age concurr drug therapi address label comment product would gener difficult address otc drug product label also note number report seriou advers reaction submit fda spontan report system includ result hospit death increas past sever year spite industri revis label incorpor warn suggest miscellan intern panel 1982 increas number report per year sinc 1986 56 105 report approxim 53 percent receiv fda sinc 1988 see section b comment 4 agenc conclud insuffici evid warn product label could adequ inform protect consum well known side effect quinin includ idiosyncrat reaction conclus base primarili sever hypersensit reaction drug product contain quinin inabl identifi predispos factor reaction frequenc reaction relationship quinin relat advers event factor ethnic age concurr drug therapi refer 1 lavi n w overview efficaci safeti quinin sulfat treat ment prevent nocturn leg cramp unpublish report sup00033 docket 77n0094 docket manag branch 2 aster r h q vel could seriou advers reaction prevent drug avail prescript unpublish report comment c176 docket 77n0094 docket manag branch 3 cooper r h f bunn hemolyt anemia harrison principl intern medicin 12th ed edit j wilson et al mcgraw hill new york pp 15311543 1991 4 blackbourn j bajrov quinine_forev ever hospit pharmaci 23 732 735 1988 11 two comment object agenc discuss safeti vitamin e 50 fr 46588 46591 contend consider bodi data demonstr safeti human exclud agenc evalu comment primarili object agenc emphasi observ one physician expert vitamin e consid data refer individu anecdot uncontrol larg subject comment provid literatur review data ref 1 2 3 support safe use vitamin e human anoth comment disagre agenc categori iii classif vitamin e individu combin quinin sulfat treatment prevent nocturn leg muscl cramp contend adequ inform alreadi exist support safeti ingredi alon combin comment includ result two new clinic studi ref 4 5 compar vitamin e quinin sulfat combin product contain vitamin e quinin sulfat placebo support safe use individu ingredi well combin ingredi indic studi subject receiv daili dose 1 600 u vitamin e either alon combin quinin sulfat one addit comment includ result third new clinic studi compar vitamin e quinin sulfat combin product contain vitamin e quinin sulfat placebo ref 6 safeti inform vitamin e deriv studi tent final monograph agenc classifi vitamin e categori iii treatment prevent nocturn leg muscl cramp state safe effect otc dosag establish use 50 fr 46588 46591 agenc evalu data submit rulemak proceed acknowledg data total bodi inform publish vitamin e agenc point paper robert ref 7 rais question safe dose otc vitamin e agenc review addit data inform submit determin suffici evid present support safeti vitamin e treatment prevent nocturn leg muscl cramp howev evid inadequ support effect vitamin e use see section c comment 13 farrel bieri ref 2 evalu potenti toxic benefici effect vitamin e intak twenti eight adult self administ 100 800 u vitamin e daili averag 3 year studi review subject past medic histori reveal appar gross evid toxic vitamin e intak highest plasma alpha tocopherol concentr vitamin e subject two time upper limit normal determin control subject broad rang laboratori test perform assess toxic effect variou organ system disturb liver kidney muscl thyroid gland erythrocyt leukocyt coagul paramet blood glucos found salkeld ref 1 review 9 000 case daili dose 3 000 u vitamin e taken 11 year 55 000 u daili 5 month subject 1 014 case vitamin e intak 200 u 3 000 u daili 11 year state side effect observ anoth 8 241 case similar intak durat mention side effect trial 82 813 subject complain one side effect report effect includ dermat pruritu ani acn cheilosi fatigu weak gastrointestin symptom prostat obstruct tachycardia vasodil thu total 10 068 case salkeld found 0 8 percent overal incid side effect advisori review panel otc vitamin miner hematin drug product reli part literatur review salkeld state conclus vitamin e safe march 16 1979 44 fr 16126 16172 advisori review panel otc antimicrobi ii drug product advanc notic propos rulemak otc topic acn drug product march 23 1982 47 fr 12430 mention notabl pharmacolog toxicolog effect oral vitamin e numer experi indic high dietari intak vitamin e 800 u daili 3 year appar without toxic side effect 47 fr 12462 one new clinic studi submit includ result laboratori test perform 24 patient evalu effect product variou organ system ref 4 test perform baselin end 1 week treatment period abnorm result liver kidney leukocyt erythrocyt platelet electrolyt blood glucos found patient time studi vitamin e use combin product subject daili intak 1 600 u vitamin e howev combin product taken 1 week studi therefor laboratori data provid use inform long term effect vitamin e second new clinic studi ref 5 four period crossov studi subject receiv 1 600 u vitamin e daili either singli combin product 5 day two four treatment period studi although laboratori test perform subject ask report advers reaction end treatment period twenti seven advers reaction report 19 subject 205 individu complet phase studi six advers reaction subject receiv vitamin e singli complaint includ abdomin cramp nausea loos bowel headach commonli occur complaint gastrointestin disturb nausea flatul diarrhea transient natur reaction consist previous report studi howev investig consid reaction relat probabl relat studi drug third new clinic studi ref 6 vitamin e 1 600 u daili 2 week compar placebo quinin sulfat combin quinin sulfat vitamin e treatment prevent nocturn leg muscl cramp detail multicent parallel design studi describ section c comment 12 vitamin e alon administ 137 subject headach frequent report advers event occur 23 subject 16 8 percent howev similar rate headach 21 percent report subject take placebo investig describ six event possibl relat studi medic advers event describ investig possibl relat vitamin e includ three four report nausea two three report myalgia one three report local edema thu daili dose 1 600 u vitamin e well toler studi bendich machlin ref 8 review six doubl blind studi involv vitamin e dose high 3 200 u daili 6 month advers effect note specif side effect consist observ studi one studi 202 colleg student receiv 600 u vitamin e placebo daili 28 day random doubl blind trial ref 9 effect prothrombin time total blood leukocyt count serum creatin phosphokinas activ evid random doubl blind placebo control studi 30 healthi adult given 800 u vitamin e placebo daili 16 week signific differ effect plasma lipid vitamin e placebo group ref 10 side effect observ doubl blind crossov studi 48 subject receiv 1 600 u vitamin e placebo daili period 6 month ref 11 report signific side effect weak fatigu thrombophleb doubl blind crossov studi 2 000 u vitamin e placebo given daili 25 adult onset diabet subject period 6 week ref 12 thyroid hormon level found ident treatment placebo period hale et al ref 13 examin incid variou clinic disord measur number laboratori variabl 369 subject use vitamin e supplement 1 861 subject subject age 65 use vitamin e appear littl influenc clinic disord hematolog biochem paramet serum glutam oxaloacet transaminas higher vitamin e user howev valu still within accept normal rang signific differ user nonus preval hypertens vagin bleed frequent headach dizzi recurr diarrhea diabetu mellitu lighthead ness thyroid disord robert ref 7 rais concern increas incid thrombophleb associ excess vitamin e intak 10 year practic robert encount 80 patient problem attribut self medic high dose vitamin e greater 800 u daili suggest vitamin e may encourag thrombosi patient predispos condit symptom thrombophleb said abat upon cessat vitamin e therapi convent treatment thrombophleb e g bed rest local heat administ along discontinu vitamin e therapi thu difficult assess action respons improv addit control studi concurr refer includ support conclus fitzgerald brash ref 14 state vitamin e 1 600 u day human decreas platelet thromboxan product could consequ reduc potenti thrombosi format addit note associ thrombophleb vitamin e use report author sever author ref 2 9 15 report oral intak high dose vitamin e produc blood coagul abnorm normal human howev individu defici vitamin k caus malabsorpt diet anticoagul therapi larg dose vitamin e exacerb coagul defect therefor high level supplement vitamin e may contraind condit ref 8 base discuss agenc conclud suffici evid exist support safeti vitamin e daili dose commonli use treatment prevent nocturn leg muscl cramp refer 1 salkeld r safeti toler high dose vitamin e administr man review literatur draft unpublish data comment c124 docket 77n0094 docket manag branch 2 farrel p j g bieri megavitamin e supplement man american journal clinic nutrit 28 13811386 1975 3 hathcock j vitamin safeti current apprais vitamin issu vol v 1 publish vitamin nutrit inform servic comment c122 docket 77n0094 docket manag branch 4 biodesign gmbh clinic evalu q velr patient nocturn leg muscl cramp draft unpublish paper comment sup00031 docket 77n0094 docket manag branch 5 leo winter associ inc final medic report data summari analysi final statist report doubl blind random crossov studi q velr versu quinin sulfat versu vitamin e versu placebo treatment nocturn leg muscl cramp 12855082 draft unpublish paper comment sup00031 docket 77n0094 docket manag branch 6 draft unpublish studi entitl short term random doubl blind parallel studi q vel vs quinin sulfat vs vitamin e vs placebo prevent treatment nocturn leg cramp comment sup00033 docket 77n0094 docket manag branch 7 robert h j perspect vitamin e therapi journal american medic associ 246 2 129131 1981 8 bendich l j machlin safeti oral intak vitamin e american journal clinic nutrit 48 612619 1988 9 tsai c et al studi effect megavitamin e supplement man american journal clinic nutrit 31 5 831837 1978 10 stampfer j et al effect vitamin e lipid american journal clinic patholog 79 6 714716 1983 11 gillilan r e b mondel j r warbass quantit evalu vitamin e treatment angina pectori american heart journal 93 4 444449 1977 12 bierenbaum l et al effect supplement vitamin e serum paramet diabet post coronari normal subject nutrit report intern 31 6 11711180 1985 13 hale w e et al vitamin e effect symptom laboratori valu elderli journal american dietet associ 86 5 625629 1986 14 fitzgerald g r brash endogen prostacyclin thromboxan biosynthesi chronic vitamin e therapi men annal new york academi scienc 393 209211 1982 15 corrigan j j effect vitamin e warfarin induc vitamin k defici annal new york academi scienc 393 361368 1982 c comment effect nocturn leg muscl cramp ingredi 12 one comment disagre agenc categori iii classif quinin sulfat treatment prevent nocturn leg muscl cramp basi lack adequ clinic data demonstr effect quinin sulfat indic 50 fr 46588 46590 comment contend suffici evid quinin effect indic present warrant classifi categori comment subsequ submit result two clinic studi ref 1 2 compar quinin sulfat vitamin e combin product contain quinin sulfat vitamin e placebo treatment prevent nocturn leg muscl cramp support effect individu ingredi quinin sulfat vitamin e well combin ingredi indic anoth comment provid result three clinic studi ref 3 4 5 felt address effect issu rais agenc tent final monograph 50 fr 46590 comment request oral hear submit data found adequ upgrad quinin sulfat categori addit respons citizen petit one comment includ result clinic studi intend demonstr efficaci combin product contain quinin sulfat vitamin e ref 6 tent final monograph agenc conclud basi review new data submit studi inform discuss intern analges miscellan intern panel quinin sulfat use otc drug product treatment prevent nocturn leg muscl cramp classifi categori iii agenc state adequ clinic data necessari support reclassif quinin categori iii categori studi address follow safeti effect issu 50 fr 46588 46590 1 quinin effect treat prevent nocturn leg muscl cramp low daili dose e g 200 325 mg short period time e g 7 day less 2 short term quinin treatment low dose significantli effect reduc recurr episod nocturn leg muscl cramp must medic taken extend period time obtain relief ye long period time 3 advers effect experienc subject expos effect dose quinin effect cours therapi agenc review addit clinic data submit determin adequ support reclassif quinin sulfat categori use three studi ref 3 4 5 compar quinin placebo one studi ref 3 75 subject enrol doubl blind random placebo control crossov studi conduct 10 week period five 2 week interv subject histori least two cramp per week least 3 month includ studi random one two treatment group group ii initi 2 week period baselin period patient fail least two cramp per week drop studi subject suffici number cramp baselin period either given placebo group 325 mg quinin sulfat per night group ii period 2 week treatment given next 2 week period fourth 2 week period subject cross altern treatment final 2 week period treatment follow subject issu weekli case report form upon instruct record number cramp experienc per night time cramp sever cramp subject also ask rate effect medic complet week 4 8 studi accord protocol subject assign treatment sequenc basi predetermin random schedul prior enter baselin period therefor remov subject studi first 2 week enough event may bias studi statist analysi studi data three efficaci variabl evalu mean frequenc leg cramp per night mean sever leg cramp per night total number night per week leg cramp occur last variabl total number night per week leg cramp occur appear construct primari data variabl list weekli case report form variabl deriv subject overal assess effect drug collect analyz sixti two 75 subject enrol studi includ data analysi 13 subject found unevalu 8 withdrew studi accord specif reason withdraw given state studi report unrel treatment remain five subject drop variou medic reason noncompli protocol intent treat analysi perform number analys carri two analys treat unblind baselin washout period treatment period type analysi incorrect crossov trial relev comparison made treatment doubl blind period possibl adjust baselin provid major chang baselin valu period patel joint test equal carryov equal pretreat sever ref 7 appli data howev signific differ seen pretreat sever second period analysi second period thu compromis therefor analysi limit first treatment period week 3 4 comparison show signific advantag quinin sulfat placebo effect variabl anoth clinic studi ref 4 use studi design studi discuss except dose quinin sulfat 260 mg night 325 mg night use first studi addit five efficaci variabl analyz frequenc sever durat leg cramp induct qualiti sleep although predetermin random chart submit studi provid enrol 74 subject 84 subject enter studi explan entri addit 10 subject provid first studi random treatment sequenc occur time entri baselin period thu subsequ remov subject prior first doubl blind treatment period may also introduc bia studi 84 subject enter baselin 69 34 assign group 35 group ii enter doubl blind treatment phase studi conclud signific differ 5 percent level exist quinin sulfat placebo three five variabl frequenc cramp induct sleep qualiti sleep howev document statist analysi support claim provid statist report accompani studi address question compar effect quinin sulfat placebo multivari analysi covari compar vector efficaci variabl four observ period two treatment period plu two washout period initi baselin valu covari conclus analysi treatment effect signific p 0 106 univari analys covari compar four observ period refer statist report p valu treatment effect provid although signific order treatment interact report also includ statist analys studi comparison four observ period separ sequenc quinin sulfat placebo placebo quinin sulfat includ baselin adjust mean comparison period use duncan multipl rang test comparison show signific differ demonstr quinin placebo placebo quinin sulfat sequenc group ii three variabl frequenc cramp qualiti sleep induct sleep howev adjust mean quinin sulfat placebo sequenc group favor placebo quinin sulfat five efficaci variabl addit first studi appropri statist analysi type studi done hypothesi equal carryov effect test reject statist test treatment effect perform result studi adequ support effect quinin sulfat treatment prevent nocturn leg muscl cramp studi jone castleden ref 5 also provid adequ evid quinin sulfat effect indic studi doubl blind crossov studi nine patient four 2 week period observ run period washout period addit two treatment period placebo quinin sulfat 300 mg day five efficaci valu second studi evalu frequenc sever durat leg cramp induct qualiti sleep raw data includ substanti statist claim made author protocol includ articl five primari efficaci variabl sever cramp claim show signific differ quinin sulfat placebo p lt 0 025 although analysi frequenc cramp 2 also claim signific p lt 0 025 indic time period 2 identifi protocol defin primari endpoint thu assum post hoc analysi done review data gener isol sever find convinc face addit publish articl provid suffici inform permit independ analysi data reason studi provid evid quinin sulfat effect treatment nocturn leg muscl cramp three studi ref 1 2 6 submit support effect quinin sulfat vitamin e individu combin treatment prevent nocturn leg muscl cramp freiburg studi ref 1 5 week doubl blind random crossov studi 24 subject subject receiv placebo week 1 baselin week 3 week 5 subject group receiv quinin week 2 combin quinin vitamin e week 4 subject group ii given combin product week 2 quinin week 4 statist signific differ frequenc attack combin product quinin sulfat report differ durat sever attack found two activ treatment report describ obviou improv frequenc durat sever attack placebo period activ treatment statist evid analysi support conclus provid moreov comparison treatment placebo involv random patient group blind portion studi compar combin product versu quinin random doubl blind trial studi report includ studi protocol detail statist analysi conduct individu subject data model describ summari data analysi properli separ carryov effect treatment effect studi provid evid control trial quinin effect nocturn leg muscl cramp studi ref 2 also employ complic random four period crossov design 205 subject randomli assign one four treatment group quinin sulfat 260 mg day vitamin e 1 600 u day combin quinin vitamin e placebo combin quinin vitamin e report statist superior compon placebo six variabl effect cramp fall asleep nighttim awaken due cramp number cramp sever cramp subject global evalu difficulti fall asleep due cramp studi also report statist signific posit find quinin sulfat versu placebo first five six variabl freiburg studi model use statist analysi properli separ carryov effect treatment effect neither data list result period provid therefor agenc unabl independ analyz result studi reli analysi provid evid report result attribut drug treatment third clinic studi compar quinin sulfat vitamin e combin quinin sulfat vitamin e placebo treatment prevent nocturn leg muscl cramp ref 6 studi multicent random block parallel design singl blind placebo run period follow 2 week doubl blind random treatment phase subject least one leg cramp per night minimum 3 night singl blind placebo week met select criteria randomli assign one four doubl blind treatment group capsul ident appear contain either placebo quinin sulfat 64 8 mg vitamin e 400 u combin quinin sulfat 64 8 mg vitamin e 400 u subject instruct take two capsul follow even meal two capsul bedtim provid daili dose 259 2 mg quinin sulfat 1 600 u vitamin e combin thereof efficaci endpoint identifi protocol 1 number episod nocturn leg cramp per week 2 sleep disturb due nocturn leg cramp 3 sever nocturn leg cramp 4 durat nocturn leg cramp howev none paramet design primari efficaci variabl protocol protocol specifi efficaci would analyz analysi varianc repeat measur test well method deem appropri basi estim 30 percent differ combin product compon assum alpha 0 05 statist power 70 percent sampl size 972 evalu subject plan 243 subject group enrol suspend howev data analyz 498 evalu subject 51 percent complet studi subject approxim evenli distribut among treatment group final report result separ analyz week 1 2 doubl blind treatment chang baselin score obtain singl blind placebo week analyz seven variabl treatment group day 7 14 use two way analysi varianc test term treatment center treatment center interact data analyz use analysi varianc repeat measur test prospect state protocol variabl 1 number night per week leg cramp 2 averag number leg cramp per night 3 averag sever leg cramp per night 4 averag durat leg cramp per night 5 averag number leg cramp per night sleep difficulti 6 averag degre difficulti get sleep per night 7 averag number night per week awaken leg cramp placebo group compar remain treatment group least signific differ test use error mean squar analysi varianc tabl within treatment group amount chang baselin efficaci paramet compar doubl blind treatment week use wilcoxon sign rank test p valu 0 05 less consid statist signific twelv center initi particip studi three center termin low enrol less four evalu subject least one treatment group low enrol center combin analysi final report number night per week leg cramp declar primari efficaci variabl baselin period mean approxim 5 night per week leg cramp record group placebo 4 72 combin 4 95 quinin sulfat 5 04 vitamin e 4 98 group improv week 1 reduct frequenc approxim 4 night per week cramp placebo 4 04 combin 3 73 quinin sulfat 3 53 vitamin e 3 97 greatest reduct subject given quinin sulfat combin product differ week 1 found statist signific compar placebo treatment group p less equal 0 04 statist signific differ quinin sulfat placebo report first week studi four six remain efficaci variabl declar secondari paramet final report quinin report significantli better placebo reduc averag number leg cramp per night averag sever leg cramp per night averag durat leg cramp per night averag number night per week sleep difficulti statist signific differ treatment group variabl report second week studi comment conclud quinin sulfat alon combin vitamin e daili dose approxim 260 mg safe effect short term 1 week treatment nocturn leg muscl cramp agenc find number flaw analysi studi first primari endpoint number night per week leg cramp appear arbitrarili chosen studi complet none efficaci variabl declar primari endpoint protocol second studi 2 week durat provis protocol separ evalu data week 1 week 2 thu basi decis analyz week 1 week 2 separ absenc analysi declar prospect protocol fact analysi week togeth see show signific benefit quinin third adjust multipl comparison includ data analysi given seven variabl two activ treatment least three time point data could analyz first week second week week nomin signific differ treatment end week one would expect retain statist signific adjust multipl comparison includ analysi even consid retrospect identifi primari endpoint correct three look week 1 week 2 togeth would least doubl nomin p valu even without correct multipl result support conclus quinin sulfat vitamin e alon combin effect treatment prevent nocturn leg muscl cramp first week 2 result fail replic result week 1 differ treatment group paramet found end week 2 investig global assess conduct end 2 week doubl blind period abl differenti treatment second signific treatment center interact found report superior quinin sulfat placebo week 1 reduc number night per week leg cramp result driven two nine center one center combin product indistinguish placebo superior placebo combin near statist signific p 0 10 thu two clinic respons favor week 1 result treatment quinin failur replic result report quinin sulfat alon vitamin e ineffect paramet measur throughout studi four retrospect declar secondari endpoint statist signific reduct report week 1 quinin sulfat group compar placebo 1 number cramp per night 2 number night sleep difficulti 3 sever cramp 4 durat cramp although consist benefit endpoint would render find primari endpoint persuas primari efficaci endpoint none differ activ treatment placebo persist end week 2 reason discuss post hoc week 1 analysi endpoint fail provid convinc evid support efficaci quinin sulfat treatment prevent nocturn leg muscl cramp two addit analys result studi submit ref 8 9 first ref 8 analysi number leg cramp per day day studi analysi show occasion day quinin superior placebo whole help given entri cramp rate one cramp episod per night least 3 night per week signific differ endpoint would expect day day e noncumul evalu second analysi ref 9 total cramp rate mean number cramp per day cours entir studi period evalu subset subject intent treat popul two analys perform group one analysi subject complet studi least 14 day treatment complet analysi analyz analysi involv result subject efficaci observ endpoint analysi quinin sulfat placebo treatment group endpoint analys less 14 day treatment complet leg cramp observ number day calcul mean carri forward 14 day none four analys reveal statist signific reduct mean number leg cramp experienc 14 day treatment quinin treat subject compar placebo subject endpoint analysi evalu patient approach statist signific quinin sulfat p 0 06 result complet analysi evalu subject intent treat analys clearli neg total cramp rate entir studi straightforward effect measur show drug effect cramp favor trend one analysi could suggest activ studi alreadi substanti size abl detect clinic meaning respons studi therefor provid evid efficaci quinin sulfat vitamin e combin thereof treatment prevent nocturn leg muscl cramp base discuss agenc conclud submit data inadequ establish effect quinin sulfat treatment prevent nocturn leg muscl cramp agenc conclud submit data adequ address safeti effect issu rais agenc tent final monograph see discuss addit agenc comment evalu data file docket manag branch ref 10 11 12 commission determin reason ground support hear hear issu warrant six clinic trial submit fail establish safeti efficaci quinin sulfat treat prevent nocturn leg muscl cramp occasion signific differ favor quinin replic within studi two crossov design studi ref 3 4 appropri analys reveal signific differ quinin sulfat placebo result larg parallel design 2 week studi show signific effect analysi 2 week data addit defici studi render report result unreli studi involv multipl endpoint none prospect declar primari efficaci variabl studi attempt correct signific level multipl endpoint design one studi permit independ evalu efficaci quinin sulfat alon ref 1 three crossov studi ref 2 3 4 treatment effect confound potenti carryov effect baselin differ 2 week parallel design studi ref 6 show effect overal entir treatment period includ investig global assess consid result week 1 separ unplan analysi signific differ quinin placebo found studi find confound signific treatment center interact reason studi cannot consid adequ well control clinic investig requir 330 10 4 ii commission conclud hear issu justifi reason state refer 1 biodesign gmbh clinic evalu q velr patient nocturn leg muscl cramp draft unpublish paper comment sup00031 docket 77n0094 docket manag branch 2 leo winter associ inc final medic report data summari analysi final statist report doubl blind random crossov studi q velr versu quinin sulfat versu vitamin e versu placebo treatment nocturn leg muscl cramp 12855082 draft unpublish paper comment sup00031 docket 77n0094 docket manag branch 3 hay r j j goodman clinic trial efficaci quinin sulfat treatment nocturn leg muscl cramp protocol 8648 draft unpublish paper comment c126 docket 77n0094 docket manag branch 4 bottner clinic trial efficaci quinin sulfat treatment nocturn leg muscl cramp protocol 8446 draft unpublish paper comment c123 docket 77n0094 docket manag branch 5 jone k c castleden doubl blind comparison quinin sulphat placebo muscl cramp age age 12 2 155158 1983 6 draft unpublish studi entitl short term random doubl blind parallel studi q vel vs quinin sulfat vs vitamin e vs placebo prevent treatment nocturn leg cramp comment sup00033 docket 77n0094 docket manag branch 7 patel h use baselin measur two period cross design commun statist theori method 12 23 26932712 1983 8 comment c159 docket 77n0094 docket manag branch 9 comment sup00041 docket 77n0094 docket manag branch 10 letter w e gilbertson fda k brien scholl inc code let00059 docket 77n0094 docket manag branch 11 letter w e gilbertson fda l fantasia ciba consum pharmaceut code let00060 docket 77n0094 docket manag branch 12 memorandum telephon convers l fantasia ciba consum pharmaceut l geismar fda januari 4 1989 code mt0009 docket 77n0094 docket manag branch 13 one comment disagre agenc categori iii classif vitamin e treatment prevent nocturn leg muscl cramp basi lack adequ clinic data demonstr effect vitamin e indic 50 fr 46588 46591 comment contend suffici evid vitamin e effect indic present warrant classifi categori comment subsequ submit result two clinic studi ref 1 2 compar vitamin e quinin sulfat combin product contain vitamin e quinin sulfat placebo treatment prevent nocturn leg muscl cramp support effect individu ingredi vitamin e quinin sulfat well combin ingredi indic addit respond citizen petit one comment includ clinic studi compar vitamin e quinin sulfat combin product contain ingredi placebo ref 3 tent final monograph agenc conclud lack control studi demonstr effect vitamin e treatment prevent nocturn leg muscl cramp agenc also determin safe effect otc dosag vitamin e establish 50 fr 46588 46591 therefor agenc classifi vitamin e categori iii use agenc review addit clinic data submit determin adequ support reclassif vitamin e categori use one doubl blind random crossov studi ref 1 combin product contain 64 8 mg quinin sulfat 400 u vitamin e lecithin base compar 64 8 mg quinin sulfat treatment prevent nocturn leg muscl cramp subject histori nocturn leg muscl cramp subject random two group subject took placebo week 1 end week 1 subject report least three cramp per week allow continu studi one group receiv combin product week 2 quinin sulfat week 4 group order revers group also receiv placebo week 3 5 quinin sulfat combin quinin sulfat vitamin e report reduc frequenc nocturn leg muscl cramp studi greater reduct frequenc leg cramp observ subject take combin product compar subject take quinin alon differ report statist signific use wilcoxon sign rank test signific differ found treatment either durat sever attack howev previous discuss see section c comment 12 studi report includ studi protocol detail statist analysi individu subject data analysi describ properli separ carryov effect treatment effect therefor possibl conclud either treatment use studi effect indic second clinic studi ref 2 doubl blind random crossov studi conduct two site involv subject least 3 month histori least two signific nocturn leg muscl cramp per week subject receiv drug first 1 week run period receiv four treatment period 5 day separ 2 day washout period includ 2 day drug free period last treatment period thu subject receiv four treatment quinin sulfat 64 8 mg combin 400 u vitamin e 64 8 mg quinin sulfat 400 u vitamin e placebo total 205 subject 209 subject origin enrol complet studi two locat morn upon aris subject record daili evalu form respons question regard difficulti failur get sleep due night leg cramp whether cramp awaken previou night subject also ask rate scale 0 cramp 3 difficult effect leg cramp abil fall asleep record number time occurr durat sever leg cramp evalu form end weekli treatment period subject ask complet global evalu form record chang condit period follow greatli improv slightli improv improv wors subject select wors ask explain comment statist analysi studi evalu follow variabl base portion subject daili evalu form global evalu treatment effect 1 number night per week subject difficulti get sleep due night leg cramp 2 effect leg cramp subject abil get sleep 3 number night per week leg cramp prevent subject go sleep 4 number night per week leg cramp woke subject 5 number leg cramp per week 6 sever leg cramp 7 subject global evalu condit chang previou week addit follow paramet deriv variabl evalu 1 number night per week leg cramp 2 mean number leg cramp per night 3 total sever score week 4 mean effect leg cramp sleep per week 5 mean sever per cramp separ analys result site analysi pool result studi cite report vitamin e found statist significantli superior placebo 7 12 efficaci variabl evalu basi combin data 6 12 variabl basi data least one locat combin found statist superior individu ingredi placebo 11 12 variabl evalu basi combin data data least one locat basi quinin sulfat found statist superior placebo 9 12 variabl evalu vitamin e 1 12 variabl comment conclud quinin vitamin e significantli addit effect addit effect result highli signific superior combin individu compon agenc determin statist analysi present studi inadequ review model use properli separ carryov effect treatment effect model consist sequenc code effect subject within code effect visit effect treatment effect given subject model say code effect constant visit thu carryov effect must partial confound treatment effect therefor analysi present cannot reli upon demonstr efficaci treatment third clinic studi multicent random block parallel design singl blind placebo run period follow 2 week doubl blind random treatment phase see section c comment 12 statist signific treatment effect vitamin e detect end doubl blind phase variabl studi agenc conclud submit data inadequ establish effect vitamin e combin vitamin e quinin sulfat treatment prevent nocturn leg muscl cramp therefor vitamin e individu combin quinin sulfat nonmonograph condit agenc detail comment evalu data file docket manag branch ref 4 5 refer 1 biodesign gmbh clinic evalu q velr patient nocturn leg muscl cramp draft unpublish paper comment sup00031 docket 77n0094 docket manag branch 2 leo winter associ inc final medic report data summari analysi final statist report doubl blind random crossov studi q velr versu quinin sulfat versu vitamin e versu placebo treatment nocturn leg muscl cramp 12855082 draft unpublish paper comment sup00031 docket 77n0094 docket manag branch 3 draft unpublish studi entitl short term random doubl blind parallel studi q vel vs quinin sulfat vs vitamin e vs placebo prevent treatment nocturn leg cramp comment sup00033 docket 77n0094 docket manag branch 4 letter w e gilbertson fda l fantasia ciba consum pharmaceut code let00060 docket 77n0094 docket manag branch 5 memorandum telephon convers l fantasia ciba consum pharmaceut l geismar fda januari 4 1989 code mt00009 docket 77n0094 docket manag branch comment label 14 sever comment request revis part label propos tent final monograph two comment disagre agenc statement ident one comment argu restat indic propos 343 150 b place agenc propos statement ident nocturn leg muscl cramp treatment prevent one comment request muscl relax pain reliev analges use comment contend suggest descript gener pharmacolog categori describ 21 cfr 201 61 anoth comment suggest chang statement night leg cramp relief argu statement would meaning layman accord 21 cfr 201 61 comment ad suggest term current use label major otc quinin product reflect contemporari descript condit treat refer warn propos 343 150 c read discontinu use ring ear deaf skin rash visual disturb occur one comment request word consult physician ad follow discontinu use comment believ warn would facilit medic treatment deem necessari comment ad agenc propos similar warn otc drug monograph exampl propos 333 50 c 2 c 3 topic acn drug product januari 15 1985 50 fr 2172 2181 comment explain addit warn would better serv elderli popul like use product one comment recommend agenc distinguish treatment prevent direct drug propos follow night leg cramp occur take 200325 mg help prevent night leg cramp take 200325 mg two hour bedtim 14 day exceed 325 mg daili comment conclud provid adequ direct use appropri discuss dosag initi onset leg muscl cramp prevent futur cramp ingredi treat prevent nocturn leg muscl cramp current gener recogn safe effect inclus otc drug monograph thu otc label final time accordingli comment request address document howev event ingredi treat prevent nocturn leg muscl cramp reach otc drug monograph statu agenc determin appropri label time publish futur issu feder regist ii agenc final conclus otc drug product treatment prevent nocturn leg muscl cramp agenc conclud data inform submit inadequ establish safeti effect quinin sulfat vitamin e combin quinin sulfat vitamin e treatment prevent nocturn leg muscl cramp three clinic studi vitamin e alon combin quinin sulfat submit report one studi provid detail statist analysi conduct model describ summari analysi fail separ carryov effect treatment effect neither protocol individu subject data provid independ verif conclus present therefor possibl basi inform provid report conclus efficaci vitamin e possibl studi anoth studi statist signific effect vitamin e report 7 12 endpoint statist signific differ placebo report 11 12 endpoint combin product studi howev treatment effect confound carryov effect make imposs ascrib observ differ vitamin e third studi larg multicent 2 week parallel design studi compar vitamin e quinin sulfat combin vitamin e quinin sulfat placebo show signific differ vitamin e compar placebo paramet end doubl blind treatment period six clinic trial submit establish safeti efficaci quinin sulfat treat prevent nocturn leg muscl cramp effect result report signific replic within studi two crossov studi signific differ quinin sulfat placebo seen second leg crossov signific pretreat differ analysi first leg crossov studi show effect quinin larg 2 week parallel studi quinin sulfat vitamin e combin ingredi versu placebo statist signific differ found activ treatment placebo full 2 week studi furthermor studi involv multipl endpoint none prospect declar primari efficaci variabl studi statist analysi conduct without regard adjust multipl comparison cast doubt valid claim statist signific mani case three crossov studi treatment effect confound potenti carryov effect make imposs attribut result studi drug agenc conclud data inform submit provid substanti evid effect quinin sulfat vitamin e combin quinin sulfat vitamin e treatment prevent nocturn leg muscl cramp final new inform rais seriou safeti concern otc avail quinin sulfat use advers event characterist quinin toxic observ healthi popul enrol clinic efficaci studi dose 260 mg 325 mg daili event includ visual auditori gastrointestin symptom fever studi auditori vestibular visual function subject given quinin confirm sensori disturb even lower dose alter pharmacokinet age result longer half life quinin older peopl suggest frequenc sever advers effect may greater elderli addit advers effect seriou unpredict hypersensit reaction quinin occur symptom often dramat lead peopl seek medic treatment hospit may requir fatal report quinin induc thrombocytopenia hypersensit reaction frequent report agenc spontan report system estim incid quinin induc thrombocytopenia unreli estim base direct evid howev suggest occurr rate 1 1 000 1 3 500 quinin drug avail otc high associ seriou hematolog sensit known factor predispos peopl develop hypersensit quinin may occur 1 week exposur month year use label warn cannot expect protect consum hypersensit reaction quinin product given benign natur nocturn leg muscl cramp failur clinic studi demonstr efficaci quinin sulfat condit evid symptom quinin toxic otc dose employ leg cramp proport target popul potenti seriou life threaten fatal hypersensit reaction quinin agenc conclud quinin safe otc use treatment prevent nocturn leg muscl cramp comment receiv respons agenc request specif comment econom impact rulemak 47 fr 43562 50 fr 46588 46593 analysi cost benefit regulatuion conduct execut order 12291 discuss tent final rule novemb 8 1985 50 fr 46588 comment receiv respons agenc tent final rule substanc analysi chang execut order 12291 supersed execut order 12866 fda examin impact final rule execut order 12866 regulatori flexibl act pub l 96354 execut order 12866 direct agenc assess cost benefit avail regulatori altern regul necessari select regulatori approach maxim net benefit includ potenti econom environment public health safeti advantag distribut impact equiti agenc believ final rule consist regulatori philosophi principl identifi execut order addit final rule signific regulatori action defin execut order thu subject review execut order regulatori flexibl act requir agenc analyz regulatori option would minim signific impact rule small entiti although final rule result remov product otc marketplac limit number product affect includ 1 combin product contain quinin sulfat vitamin e 2 product contain quinin sulfat alon label treatment prevent nocturn leg muscl cramp 3 product contain vitamin e alon label claim 4 product market otc claim initi introduct deliveri introduct interst commerc otc drug product label treatment prevent nocturn leg muscl cramp allow effect date final rule quinin current avail otc drug treat chill fever malaria base agenc review current market product appear approxim two third quinin contain product market antimalari use approxim one third treatment prevent nocturn leg muscl cramp otc quinin drug product antimalari use discuss futur issu feder regist vitamin e current avail otc use vitamin final rule affect continu market avail product contain vitamin provid product label treatment prevent nocturn leg muscl cramp product contain quinin sulfat vitamin e may relabel reformul necessari e g combin product remain marketplac allow claim describ accordingli agenc certifi final rule signific econom impact substanti number small entiti therefor regulatori flexibl act analysi requir agenc determin 21 cfr 25 24 c 6 action type individu cumul signific effect human environ therefor neither environment assess environment impact statement requir list subject 21 cfr part 310 administr practic procedur drug label medic devic report recordkeep requir therefor feder food drug cosmet act author deleg commission food drug 21 cfr part 310 amend follow part 310_new drug 1 author citat 21 cfr part 310 continu read follow author sec 201 301 501 502 503 505 506 507 512 516 520 601 701 704 705 721 feder food drug cosmet act 21 u c 321 331 351 352 353 355 356 357 360b360f 360j 361 371 374 375 379e sec 215 301 302 351 354360f public health servic act 42 u c 216 241 242 262 263b263n 2 new 310 546 ad subpart e read follow 310 546 drug product contain activ ingredi offer counter otc treatment prevent nocturn leg muscl cramp quinin sulfat alon combin vitamin e present counter otc drug product treatment prevent nocturn leg muscl cramp e condit local pain lower extrem usual occur middl life beyond regular pattern concern time sever lack adequ data establish gener recognit safeti effect quinin sulfat vitamin e ingredi otc use treatment prevent nocturn leg muscl cramp dose use treat prevent condit quinin sulfat caus advers event transient visual auditori disturb dizzi fever nausea vomit diarrhea quinin sulfat may caus unpredict seriou life threaten hypersensit reaction requir medic intervent hospit fatal report risk associ use quinin sulfat absenc evid effect outweigh potenti benefit treat prevent benign self limit condit base upon advers benefit risk ratio drug product contain quinin quinin sulfat cannot consid gener recogn safe treatment prevent nocturn leg muscl cramp b otc drug product label repres promot treatment prevent nocturn leg muscl cramp regard new drug within mean section 201 p feder food drug cosmet act act approv applic abbrevi applic section 505 act part 314 chapter requir market absenc approv new drug applic abbrevi new drug applic product also misbrand section 502 act c clinic investig design obtain evid drug product label repres promot otc use treatment prevent nocturn leg muscl cramp safe effect purpos intend must compli requir procedur govern use investig new drug set forth part 312 chapter februari 22 1995 otc drug product initi introduc initi deliv introduct interst commerc complianc section subject regulatori action date august 4 1994 supplem signer michael r taylor signer signjob deputi commission polici signjob frfile fr doc 9420449 file 81994 8 45 frfile bill bill code 416001f bill